Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Zacks: Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Given $13.33 Average Target Price by Brokerages

Posted on February 9, 2016--- Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus target price of $13.33 for the company and are anticipating that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Anthera Pharmaceuticals an industry rank of 70 out of 265 based on the ratings given to related companies.

Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 2.46 on Thursday. The stock has a 50 day moving average of $3.64 and a 200 day moving average of $6.21. Anthera Pharmaceuticals has a one year low of $2.28 and a one year high of $11.65. The firm’s market cap is $98.09 million.



Separately, Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th.

In other news, insider Colin Hislop sold 12,500 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were sold at an average price of $5.31, for a total transaction of $66,375.00. Following the completion of the transaction, the insider now owns 19,147 shares of the company’s stock, valued at $101,670.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

12 Month Chart for NASDAQ:ANTH

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com
http://sleekmoney.com/zacks-anthera-pharmaceuticals-inc-nasdaqanth-given-13-33-average-target-price-by-brokerages/927448/